Project Grant R21HL184189
Award Date 4/1/26
Completion Date 1/31/28
Dollars Obligated $134K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $177,120 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 19, 2025, and an ultimate completion date of August 31, 2030. The research initiative, titled "Characterizing Biological Aging for Heart and Lung Diseases Using Multi-Omics Ageotypes," focuses on developing and validating...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $249,000 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective March 10, 2026, with an ultimate completion date of February 28, 2029. The award supports a three-year research initiative titled "Using Genomic Modifiers to Mechanistically Link Clonal Hematopoiesis of Indeterminate Potential Penetrance to Coronary Artery...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Harvard Medical School a Project Grant of $125,532 under the Cardiovascular Diseases Research program (CFDA 93.837) to support research interrogating the clonal architecture of human hematopoiesis through mitochondrial lineage tracing. The award, effective June 30, 2025, with an ultimate completion date of January 31, 2029, funds investigator-initiated research addressing the decline of hematopoietic stem...
- Federal Grant Award Summary Brigham and Women's Hospital Inc. received an $800,962 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), with an award date of September 15, 2025, and ultimate completion date of June 30, 2030. This research initiative investigates endothelial inflammation, Src kinase dysregulation, and fibrosis mechanisms in early pulmonary arterial hypertension (PAH), with particular...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $166,644 to The Trustees of Columbia University in the City of New York (Health Sciences Division) on July 16, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). The award supports research investigating inflammatory responses in human hematopoietic stem cells (HSCs) with a focus on understanding how aging and clonal hematopoiesis—specifically TET2 mutations—alter...
- Federal Grant Award Summary Dana-Farber Cancer Institute, Inc. received a $445,000 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded on March 10, 2026, with a completion date of December 31, 2032. The award funds research to elucidate the origins and drivers of clonal dynamics in hematopoiesis—the process by which hematopoietic stem cells (HSCs) in bone marrow replenish blood cell populations. The...
- Federal Project Grant Award Summary Brigham and Women's Hospital Inc. received a $710,302 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 1, 2025, through May 31, 2029. This award funds research characterizing lung interstitial neutrophils (LINs), a specialized subset of immune cells with significant bactericidal activity. The project investigates the origin, functional state, and...
- Federal Grant Award Summary Brigham & Women's Hospital Inc. received a $855,585 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 20, 2025, with completion scheduled for July 31, 2028. This award funds preparatory research to adapt and test an antihypertensive self-titration intervention for implementation in the U.S. primary care context. The project addresses the significant public...
- Federal Grant Award Summary Boston Medical Center Corporation received a $1.42 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective May 1, 2025, through February 28, 2030. The award supports research to elucidate the endothelial mechanisms that regulate hematopoietic stem cell (HSC) extravasation—the process by which circulating stem cells cross blood vessel walls and enter their bone marrow...
- Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,072,936 to the University of California, San Diego, effective September 15, 2025, through June 30, 2029, under the Cardiovascular Diseases Research program (CFDA 93.837). The research initiative, titled "Protein Aggregation in Hematopoietic Stem Cells," investigates proteostasis dysfunction as a mechanism underlying hematopoietic stem cell (HSC) aging. The project focuses...